心房分流装置对射血分数保留心衰患者心脏结构与功能的影响:REDUCE LAP-HF II 随机临床试验
该研究为 REDUCE LAP-HF II 试验的事后分析,纳入 621 例 HFpEF/HFmrEF 患者,比较心房分流装置与假手术对照对心脏结构与功能的影响。结果显示分流组左心室舒张末期容积和左心房最小容积降低,左心室收缩组织多普勒速度和左心房排空分数改善,但右心室和右心房容积增加,右心室收缩功能无变化。在应答者中,右心室容积增加更小,提示分流血液更易通过肺循环实现左心房卸载。
要点
- 心房分流装置可逆转左心重构并增加右心容积,但不影响右心室收缩功能。
- 应答者(无潜在肺血管疾病且无心脏节律管理设备)的右心容积增加更小,左心房卸载更有效。
- 该事后分析支持既往提出的应答者假设,但需更长随访进一步验证。
核心结论
- 在 REDUCE LAP-HF II 试验的事后分析中,随访 2 年,心房分流导致左侧心腔逆重构和右侧心腔容积增加,与分流血流一致,但右心室收缩功能无变化。
- 应答者接受分流治疗后心脏结构与功能变化比非应答者更有利,支持既往识别的应答者组假设和机制。
研究设计与样本
- 该研究为假手术对照随机临床试验的事后分析,纳入射血分数保留或轻度降低的心衰患者,来自 89 个国际医疗中心,具有可评估的超声心动图扫描。
- 改良意向性治疗分析纳入 621 例随机患者,中位年龄 72.0 岁(IQR 66.0-77.0),女性 382 例(61.5%),分流组 309 例(49.8%),假手术对照组 312 例(50.2%)。
- 干预为心房分流装置或假手术对照,主要结局为基线至术后 1、6、12、24 个月超声心动图指标的变化。
主要发现
- 在总体试验人群中,与假手术相比,分流组降低左心室舒张末期容积(平均差 -5.65 mL;P <.001)、左心房最小容积(平均差 -2.8 mL;P =.01),并改善左心室收缩组织多普勒速度(平均差 0.69 cm/s;P <.001)和左心房排空分数(平均差 1.88 个百分点;P =.02)。
- 分流治疗还增加右心室容积(平均差 9.58 mL;P <.001)和右心房容积(平均差 9.71 mL;P <.001),但对右心室收缩功能、肺动脉压力和右心房压力无影响。
- 在分流组中,应答者与非应答者相比,右心室舒张末期容积增加更小(平均差 5.71 mL vs 15.18 mL;交互 P =.01),右心室收缩末期容积增加更小(平均差 1.58 mL vs 7.89 mL;交互 P =.002),右心室/左心室比值增加更小(平均差 0.07 vs 0.20;交互 P <.001),而二尖瓣 A 波速度增加更大(平均差 5.08 cm/s vs -1.97 cm/s;交互 P =.02)。
临床怎么用
- 对于 HFpEF/HFmrEF 患者,心房分流装置可改善左心重构和功能,但需注意右心容积增加,应评估右心功能及肺血管状态。
- 应答者(无潜在肺血管疾病且无心脏节律管理设备)可能从心房分流治疗中获益更多,支持筛选合适患者。
局限性
- 该研究为事后分析,需更长随访进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although the results of A Study to Evaluate the Corvia Medical Inc IASD System II to Reduce Elevated Left Atrial Pressure in Patients with Heart Failure (REDUCE LAP-HF II) trial were neutral overall, atrial shunt therapy demonstrated potential efficacy in responders (no latent pulmonary vascular disease and no cardiac rhythm management device). Post hoc analyses were conducted to evaluate the effect of shunt vs sham stratified by responder status. OBJECTIVE: To evaluate the effect of atrial shunt vs sham control on cardiac structure/function in the overall study and stratified by responder status. DESIGN, SETTING, AND PARTICIPANTS: This was a sham-controlled randomized clinical trial of an atrial shunt device in heart failure with preserved ejection fraction (HFpEF)/HF with mildly reduced EF (HFmrEF). Trial participants with evaluable echocardiography scans were recruited from 89 international medical centers. Data were analyzed from April 2023 to January 2024. INTERVENTIONS: Atrial shunt device or sham control. MAIN OUTCOME MEASURES: Changes in echocardiographic measures from baseline to 1, 6, 12, and 24 months after index procedure. RESULTS: The modified intention-to-treat analysis of the REDUCE LAP-HF II trial included 621 randomized patients (median [IQR] age, 72.0 [66.0-77.0] years; 382 female [61.5%]; shunt arm, 309 [49.8%]; sham control arm, 312 [50.2%]). Through 24 months, 212 of 217 patients (98%) in the shunt arm with evaluable echocardiograms had patent shunts. In the overall trial population, the shunt reduced left ventricular (LV) end-diastolic volume (mean difference, -5.65 mL; P <.001), left atrial (LA) minimal volume (mean difference, -2.8 mL; P =.01), and improved LV systolic tissue Doppler velocity (mean difference, 0.69 cm/s; P <.001) and LA emptying fraction (mean difference, 1.88 percentage units; P =.02) compared with sham. Shunt treatment also increased right ventricular (RV; mean difference, 9.58 mL; P <.001) and right atrial (RA; mean difference, 9.71 mL; P <.001) volumes but had no effect on RV systolic function, pulmonary artery pressure, or RA pressure compared with sham. In the shunt arm, responders had smaller increases in RV end-diastolic volume (mean difference, 5.71 mL vs 15.18 mL; interaction P =.01), RV end-systolic volume (mean difference, 1.58 mL vs 7.89 mL; interaction P =.002), and RV/LV ratio (mean difference, 0.07 vs 0.20; interaction P <.001) and larger increases in transmitral A wave velocity (mean difference, 5.08 cm/s vs -1.97 cm/s; interaction P =.02) compared with nonresponders randomized to the shunt, suggesting greater ability to accommodate shunted blood through the pulmonary circulation enabling LA unloading. CONCLUSIONS AND RELEVANCE: In this post hoc analysis of the REDUCE LAP-HF II trial, over 2 years of follow-up, atrial shunting led to reverse remodeling of left-sided chambers and increases in volume of right-sided chambers consistent with the shunt flow but no change in RV systolic function compared with sham. Changes in cardiac structure/function were more favorable in responders compared with nonresponders treated with the shunt, supporting the previously identified responder group hypothesis and mechanism, although further evaluation with longer follow-up is needed. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03088033.
引用
- Patel, Silvestry, Komtebedde, et al. Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical Trial. JAMA Cardiol. 2024. PMID: 38630494. doi:10.1001/jamacardio.2024.0520
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。